Initial and Long-Term Results of Endovascular Therapy for Chronic Total Occlusion of the Subclavian Artery

2011 ◽  
Vol 35 (2) ◽  
pp. 255-262 ◽  
Author(s):  
Srdjan Babic ◽  
Dragan Sagic ◽  
Djordje Radak ◽  
Zelimir Antonic ◽  
Petar Otasevic ◽  
...  
Keyword(s):  
Subclavian Artery ◽  
Endovascular Therapy ◽  
Chronic Total Occlusion ◽  
Long Term Results ◽  
Total Occlusion

scholarly journals Percutaneous endovascular therapy for symptomatic chronic total occlusion of the left subclavian artery

2018 ◽  
Vol 59 (10) ◽  
pp. 534-538
Author(s):  
M Akif Cakar ◽  
E Tatli ◽  
A Tokatli ◽  
H Kilic ◽  
H Gunduz ◽  
...  
Keyword(s):  
Subclavian Artery ◽  
Endovascular Therapy ◽  
Chronic Total Occlusion ◽  
Left Subclavian Artery ◽  
Total Occlusion

scholarly journals LONG-TERM OUTCOMES OF ENDOVASCULAR THERAPY FOR CHRONIC TOTAL OCCLUSION OF THE SUPERFICIAL FEMORAL ARTERIES

2012 ◽  
Vol 59 (13) ◽  
pp. E2089
Author(s):  
Junya Matsumi ◽  
Satoshi Takeshita ◽  
Shigeru Saito ◽  
Takeshi Akasaka ◽  
Yutaka Tanaka ◽  
...  
Keyword(s):  
Endovascular Therapy ◽  
Chronic Total Occlusion ◽  
Long Term Outcomes ◽  
Total Occlusion ◽  
Femoral Arteries

scholarly journals Long-term follow-up of therapeutic efficacy of everolimus-eluting bioresorbable vascular scaffold in comparison to everolimus-eluting stent in treatment of chronic total occlusion guided by intracoronary imaging

2020 ◽  
Vol 72 (1) ◽  
Author(s):  
Mohammad Abdallah Eltahlawi ◽  
Abdel-Aziz Fouad Abdel-Aziz ◽  
Abdel-Salam Sherif ◽  
Khalid Abdel-Azeem Shokry ◽  
Islam Elsayed Shehata
Keyword(s):  
Chronic Total Occlusion ◽  
Bioresorbable Vascular Scaffold ◽  
Total Occlusion ◽  
Intracoronary Imaging ◽  
Group I ◽  
Significant Difference ◽  
Vascular Scaffold ◽  
Long Term Follow Up

Abstract Background We hypothesized that 1st generation everolimus-eluting bioresorbable vascular scaffold (BVS) stent associated with less complication and less restenosis rate than everolimus-eluting stent (EES) in chronic total occlusion (CTO) recanalization guided by intracoronary imaging. Therefore, we aimed to assess the safety and performance of BVS stent in CTO revascularization in comparison to EES guided by intracoronary imaging. Our prospective comparative cross-sectional study was conducted on 60 CTO patients divided into two groups according to type of stent revascularization: group I (EES group): 40 (66.7%) patients and group II (BVS group): 20 (33.3%) patients. All patients were subjected to history taking, electrocardiogram (ECG), echocardiography, laboratory investigation, stress thallium study to assess viability before revascularization. Revascularization of viable CTO lesion guided by intracoronary imaging using optical coherence tomography (OCT). Then, long-term follow-up over 1 year clinically and by multi-slice CT coronary angiography (MSCT). Our clinical and angiographic endpoints were to detect any clinical or angiographic complications during the follow-up period. Results At 6 months angiographic follow-up, BVS group had not inferior angiographic parameters but without statistically significant difference (p = 0.566). At 12 months follow-up, there was no difference at end points between the two groups (p = 0.476). No differences were found at angiographic or clinical follow-up between BVS and EES. Conclusion This study shows that 1st generation everolimus-eluting BVS is non-inferior to EES for CTO revascularization. Further studies are needed to clearly state which new smaller footprint BVS, faster reabsorption, magnesium-based less thrombogenicity, and advanced mechanical properties is under development. We cannot dismiss the efficacy and safety of new BVS technology. Trial registration ZU-IRB#2498/3-12-2016 Registered 3 December 2016, email: [email protected]

Sign in / Sign up

Export Citation Format

Share Document